Clinical Trial Update: A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of T0903131 (INT131) besylate for type 2 diabetes; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• T0903131 (INT131) besylate (INT131 besylate)

Snippet

Sponsor: InteKrin Therapeutics, Inc. | Conditions: Diabetes Mellitus, Type II | Phase 2 | Status: COMPLETED